• Cefazedone (Refosporen): Data-Driven Solutions for Reliable

  2026-05-05

  This article explores real-world laboratory challenges in cell viability and antibacterial assays, demonstrating how Cefazedone (Refosporen) (SKU BA1102) from APExBIO addresses reproducibility, sensitivity, and workflow integrity. Evidence-based scenarios guide biomedical researchers and technicians in optimizing experimental outcomes using validated protocols.

• Npt1-Mediated Renal Transport Mechanism of Faropenem Sodium

  2026-05-04

  This study elucidates the renal secretion pathway of faropenem sodium, a penem antibiotic, revealing that the inorganic phosphate transporter Npt1 at the renal luminal membrane plays a key role in its active transport. The findings clarify pharmacokinetic elimination routes and inform rational antibiotic selection and resistance research strategies.

• Aztreonam: Applied Protocols for Gram-Negative Bacterial Res

  2026-05-04

  Aztreonam, a monocyclic β-lactam antibiotic, excels in targeted Gram-negative bacterial assays and advanced resistance modeling. This article delivers actionable protocols, workflow optimizations, and troubleshooting strategies, leveraging both recent clinical research and hands-on laboratory experience for next-generation antimicrobial studies.

• Sodium Dicloxacillin Monohydrate: Precision PK/PD for MSSA R

  2026-05-03

  Explore how sodium dicloxacillin monohydrate drives innovation in Gram-positive bacterial infection research, with a deep dive into its PK/PD optimization, intracellular efficacy, and evidence-driven protocol parameters for MSSA models. This article uniquely focuses on translational assay design and product selection strategies.

• Levofloxacin: Bridging Antibacterial Action and Bone Researc

  2026-05-02

  This thought-leadership article explores how Levofloxacin, a synthetic fluoroquinolone antibiotic, is redefining translational research at the intersection of infectious disease and bone metabolism. Drawing on mechanistic insights, validated protocols, and the latest resistance landscape, we provide actionable guidance for researchers. The article uniquely positions APExBIO’s Levofloxacin as a precision tool, advancing both antibacterial and osteometabolic investigations beyond the confines of typical product guides.

• Faropenem Sodium: Protocol Enhancements for Anaerobic Infect

  2026-05-02

  Faropenem sodium, a penem antibiotic from APExBIO, delivers robust inhibition of bacterial cell wall synthesis—including in challenging anaerobic and resistant bacterial models. This article details actionable workflows, protocol optimizations, and troubleshooting strategies that leverage Faropenem sodium’s unique transporter interactions and broad-spectrum profile for reproducible, high-sensitivity research.

• Mubritinib (TAK 165): Redefining OXPHOS Inhibition in AML &

  2026-05-01

  This thought-leadership article from APExBIO’s scientific marketing head explores the mechanistic, translational, and strategic landscape of Mubritinib (TAK 165) as a mitochondrial complex I inhibitor with emerging roles in acute myeloid leukemia (AML), primary effusion lymphoma (PEL), and viral oncology, contrasting its unique utility with historic HER2 paradigms. With a synthesis of mechanistic insight, protocol guidance, and evidence-based perspective, the article empowers translational researchers to leverage Mubritinib in next-generation cancer and virology research.

• Pharmacokinetics of Temafloxacin: Evidence and Veterinary Pa

  2026-04-30

  This article reviews the pharmacokinetic profile of temafloxacin, highlighting its bioavailability, tissue distribution, and elimination pathways as reported by Dudley (1991). These findings inform dosing strategies and provide a benchmark for comparative studies with veterinary antibiotics such as Sulfamonomethoxine (SMM), especially in contexts of environmental safety and antimicrobial stewardship.

• Streptavidin-Cy3: Precision Biotin Detection in Cancer Resea

  2026-04-30

  Streptavidin-Cy3 elevates biotin detection workflows with exceptional sensitivity and specificity, empowering researchers to unravel complex biomolecular interactions in oncology. This article details practical protocols, advanced use-cases, and troubleshooting insights for maximizing the value of this fluorescent streptavidin conjugate from APExBIO.

• Amikacin (BAY416651) in Antibiotic Resistance Research Workf

  2026-04-29

  Amikacin (BAY416651) stands out for its resistance to most aminoglycoside-modifying enzymes and proven utility in dissecting resistance mechanisms in multidrug-resistant pathogens. This article translates cutting-edge delivery methods and troubleshooting insights into actionable protocols for maximizing research impact using APExBIO's Amikacin.

• Atorvastatin: Applied Protocols for HMG-CoA Reductase Inhibi

  2026-04-29

  Atorvastatin, a premier HMG-CoA reductase inhibitor, is redefining experimental strategy in cholesterol metabolism, vascular cell biology, and ferroptosis-driven oncology research. This guide bridges cutting-edge reference data with actionable protocols, troubleshooting tips, and comparative insights for maximizing translational impact in your lab.

• Catalpol in Diabetes: Pharmacology, Mechanisms, and Preclini

  2026-04-28

  This review synthesizes evidence on Catalpol’s multi-target pharmacological actions against diabetes and its complications, highlighting its modulation of inflammatory and metabolic signaling pathways. The study’s comprehensive pharmacokinetic and safety analysis positions Catalpol as a promising scaffold for anti-diabetic drug development and translational research.

• Carfilzomib (PR-171): Optimizing Proteasome Inhibition Workf

  2026-04-28

  Carfilzomib (PR-171) enables robust, multi-modal cell death induction in cancer models, especially when paired with radiation therapies. This guide delivers advanced protocols, troubleshooting insights, and translational best practices to harness Carfilzomib’s full potential in proteasome inhibition research.

• Gene Expression Profiling Predicts Olaparib Response in MPM

  2026-04-27

  Borchert et al. (2019) demonstrate that specific homologous recombination repair (HRR) gene expression patterns, including BAP1 mutations, predict susceptibility to the PARP inhibitor Olaparib in malignant pleural mesothelioma (MPM). Their findings suggest a subset of MPM patients may benefit from PARP inhibition, especially in combination with cisplatin, guiding future precision oncology strategies.

• Cefodizime (SKU BA1050): Reliable Antibiotic for Lab Assays

  2026-04-27

  This article provides an evidence-based, scenario-driven guide for bench scientists and biomedical researchers evaluating 'Cefodizime' (SKU BA1050) as a third-generation cephalosporin antibiotic for cell viability and resistance assays. It addresses real-world workflow challenges, interprets recent resistance data, and details best-practice parameters—empowering labs to make informed, reproducible choices with APExBIO’s Cefodizime.

447 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page